AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04261907 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lopinavir/ritonavir group
Description: Lopinavir/ritonavir tablets(200mg / 50mg tablet), two tablets each time, twice daily, for 14 days, +conventional standardized treatment
Study NCT02542553 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral BAL
Study NCT03268707 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemetric smartphone application
Description: Structured follow up with a telemetric smartphone application
Study NCT03268707 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional follow up
Description: Conventional follow up at physician practice
Study NCT00444379 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir
Description: Lopinavir/ritonavir 200/50mg plus Emtricitabine/Tenofovir 200/300mg versus Efavirenz 600mg plus Emtricitabine/Tenofovir 200/300mg
Study NCT03223844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine Sulfate
Description: Repeated oral administration of dexamphetamine 0.4mg/KG bodyweight four times.
Study NCT04061148 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIRSIT
Description: NIRSIT is a device that utilizes Near Infrared Spectroscopy to provide a non-invasive measurement of frontal lobe blood oxygenation over time.
Study NCT04061148 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: NIRSIT
Description: NIRSIT is a device that utilizes Near Infrared Spectroscopy to provide a non-invasive measurement of frontal lobe blood oxygenation over time.
Study NCT01479699 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Olive leaf extract capsules
Description: Four capsules taken at baseline each containing 4mg oleuropein
Study NCT02954991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glesatinib
Description: Glesatinib is a small molecule multi-targeted receptor tyrosine kinase inhibitor
Study NCT02954991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases.
Study NCT02954991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mocetinostat
Description: Mocetinostat is an HDAC inhibitor.
Study NCT02954991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: nivolumab is a programmed death receptor-1 (PD-1) blocking antibody
Study NCT03159338 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet rich fibrin
Description: Platelet rich fibrin will be prepared by taking 20 cc blood and centrifugation with 28000 rpm.
Study NCT03159338 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In control group , after spliting the osteotomy site before fixation a placebo gel will be placed
Study NCT01128608 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 24-Hr Esohpageal pH Monitoring
Description: There will be a 24-hr pH monitoring procedure and two 10-minute infusions each one week apart consisting of high PCO2 solution and 0.1 N HCI solution.
Study NCT01128608 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCO2 Acid Perfusion and 0.1N HCI Perfusion
Description: A small tube will be inserted through the nostril and into the esophagus. A mild CO2 solution or a mild saline solution will be administered for aprox. 10 minutes during which you will be asked questions regarding any symptoms you may experience.
Study NCT04251572 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood sampling
Study NCT04251572 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionaires
Description: Included participants will complete a baseline questionnaire at end of treatment (EOT) and a follow-up questionnaire throughout the follow-up period (Table 1). The questionnaires collect information on socio-demographics (age, gender, ethnicity, employment status, education level, housing status, incarceration, medical history and OST), injecting drug use (drugs injected, injection frequency and sharing of needle/syringe, cookers, cotton/filter or water). Details on the received DAA regime including mode of administration (direct observed therapy, pill box, etc.) and self-reported data on treatment adherence will also be recorded.
Study NCT00176423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: galantamine
Description: see arm/group description
Study NCT00176423 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: galantamine
Description: see arm/group description
Study NCT03573778 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iHEAL
Description: Women work with a Registered Nurse in 10-18 visits (over 6 months) that focus on 6 inter-related 6 components (areas): Safeguarding, Managing Symptoms, Getting Basics, Cautiously Connecting, Regenerating Family, Renewing Self. Using a standard 3 phase process, and guided by 5 principles, the nurse discusses each of these components with the woman in order to identify the woman's needs, experiences and priorities. The nurse then provides personalized support to assist the woman in address the concerns that she sees as most important for her health and well-being; this support includes linking women to existing services if she chooses.
Study NCT03573778 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information about Community Services
Description: Women are provided with information about community services appropriate for women experiencing intimate partner violence and consistent with what service providers might recommend (usual care). Women are encouraged to use this information as they see fit.
Study NCT03047330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol withdrawal
Description: one injection of open-label intramuscular dose of leuprolide (3.75-mg depot), a gonadotropin-releasing hormone agonist that rapidly suppresses estradiol and temporarily achieves ovarian suppression.
Study NCT03047330 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fragmented sleep
Description: Fragmented sleep will be experimentally induced.
Study NCT02627651 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive and motor assignments
Description: walking on treadmill, performing cognitive assignment; and performing the cognitive assignment while walking .
Study NCT02627651 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cognitive and motor assignments
Description: walking on treadmill, performing cognitive assignment; and performing the cognitive assignment while walking .
Study NCT02046486 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor 180mg whole tablets
Study NCT02046486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 180mg crushed and dispersed
Study NCT00323856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alphanate SD/HT
Description: Plasma-derived preparation of Factor VIII
Study NCT03740282 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lapiplasty
Description: Patients 14 years through 58 years with symptomatic hallux valgus who are treated with the Lapiplasty System will begin weight-bearing by 3 weeks and follow a defined post-operative protocol.
Study NCT01450020 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: Receive ACS material
Study NCT01450020 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: educational intervention
Description: Receive ACS material
Study NCT01450020 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01450020 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01450020 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: counseling intervention
Description: Undergo PN session
Study NCT01450020 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: survey administration
Description: Ancillary studies
Study NCT01450020 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: survey administration
Description: Ancillary studies
Study NCT01450020 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT01450020 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT00702533 — intervention group
Intervention type: DRUG
Intervention: Pentagastrin
Study NCT03851796 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TEENS+Parents as Coaches
Description: Parents as Coaches teaches parenting strategies to facilitate healthy weight loss in adolescent children; adolescents are in a group based behavioral weight management treatment.
Study NCT03851796 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TEENS+Parent Weight Loss
Description: Parent Weight loss teaches core behavioral weight loss strategies and techniques for parent weight loss; adolescents are in a group based behavioral weight management treatment.
Study NCT00353158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: 100mg twice daily for 3 days. Two hours after the last dose of doxycycline is taken in the clinic, on-medication phototesting with ssUVR, UVA, and visible light will be performed.
Study NCT00353158 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voriconazole
Description: After taking voriconazole for (Bullet)7 days to achieve a steady state of voriconazole for subjects, on-medication phototesting with ssUVR, UVA, and visible light will be performed.
Study NCT06025617 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diagnostic evaluation at the Diagnostic Clinic for Functional Disorders
Description: The intervention consists of being examined at the Diagnostic Clinic for Functional Disorders. If an FSD diagnosis is established, the patient receives feed-back of on the FSD diagnosis and patient education about the condition. Subsequently, the clinic provides guidance to the GP regarding recommended management and treatment options tailored to each individual patient.
Study NCT06025617 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic as usual
Description: Diagnostic as usual consists in being referred to be examined at another existing specialist clinic in the secondary sector, as specified by the patient's GP.
Study NCT04235777 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT)
Description: A fixed dose of 8 Gy x 3 fractions sequential or concurrent with M7824 and PDS01ADC
Study NCT04235777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDS01ADC
Description: An initial dose of 16.8 mcg/kg administered subcutaneously every 4 weeks while on M7824 and with or without SBRT
Study NCT04235777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M7824
Description: 1200 mg administered IV every two weeks while on PDS01ADC and with or without SBRT
Study NCT02542033 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: treated apple juice with low sugar content
Description: Each study participant consumed 500 mL test juice at the morning of the interventional day. The 500 mL bottle content had to be ingested within 5 minutes. an intravenous catheter was inserted into a forearm vein for blood withdrawal at baseline, directly before (time point 0) and 15, 30, 45, 60, 90 and 120 minutes after starting the ingestion of the test product. From all samples plasma insulin was measured. From the blood samples taken at baseline and 120 minutes after consumption of the test product safety parameters were determined. Capillary blood was taken from the finger pad using a HemoCue® Safety Lancet at baseline (twice) and once directly before (time point 0) and 15, 30, 45, 60, 90 and 120 minutes after ingestion of the test product.
Study NCT02542033 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: un-treated apple juice with normal sugar content
Description: Each study participant consumed 500 mL test juice at the morning of the interventional day. The 500 mL bottle content had to be ingested within 5 minutes. an intravenous catheter was inserted into a forearm vein for blood withdrawal at baseline, directly before (time point 0) and 15, 30, 45, 60, 90 and 120 minutes after starting the ingestion of the test product. From all samples plasma insulin was measured. From the blood samples taken at baseline and 120 minutes after consumption of the test product safety parameters were determined. Capillary blood was taken from the finger pad using a HemoCue® Safety Lancet at baseline (twice) and once directly before (time point 0) and 15, 30, 45, 60, 90 and 120 minutes after ingestion of the test product.
Study NCT01174121 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Young TIL
Description: Day 0: Cells will be infused intravenously (IV) on the Patient Care Unit over 20-30 minutes (one to four days after the last dose of fludarabine).
Study NCT01174121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses.)
Study NCT01174121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with Mesna 15 mg/kg/day X2 days over 1 hr.
Study NCT01174121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
Study NCT03927014 — intervention group
Intervention type: OTHER
Intervention: thiol/disulfide levels
Description: Venous blood will sample from the antecubital veins for measuring the serum concentration of thiol/disulfide levels. The serum thiol/disulfide levels will measure using commercially available reagent kits, which is produced to detect human thiol/disulfide levels (Rel Assay Diagnostics Gaziantep, Turkey). The thiol/disulfide levels measurements were performed in accordance with the company's protocol.
Study NCT01370200 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: plasma exchange treatment
Description: the therapeutic plasma exchange is the procedure of removing the plasma of the patient including pathological macromolecules and replacing it with the replacement fluid
Study NCT01174121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (Keytruda)
Description: Arm 3: Pembrolizumab 2mg/kg IV over approximately 30 minutes on Days -2, 21, 42, and 63 Arm 4: Pembrolizumab 2mg/kg IV over approximately 30 minutes (for patients who meet progressive disease per RECIST criteria and have resolved major toxicities after cell infusion or anytime during the post-treatment evaluation period; starting within 4 weeks of progression; may receive up to 8 doses every 3 weeks).
Study NCT01260090 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation;
Description: Name of the Device:~We will use the PMA approved version of the NCP System, including the NCP Generator (model 103), NCP Programming Wand (model 201), NCP Programming Software (model 250v7.1), NCP Lead (model 304), NCP Tunneling Tool (model 402) and the Patient Magnet (model 220).~FDA Facility Registration Number: 1644487
Study NCT01260090 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: No stimulation
Description: Vagus nerve stimulation
Study NCT01418703 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed Loop Control (CLC)
Description: In this study, the researchers compared the management of diabetes during physical activity and meals with the closed-loop system developed at the University of Virginia. This Control to Range System uses two DexCom Seven Continuous Glucose Monitor, a computer containing an investigational control algorithm (well-defined instructions that are expressed in mathematical equations), and an OmniPod Insulin Management System, a portable subcutaneous (under the skin) insulin pump. During the closed-loop admission, the computer used CGM values to make recommendations of insulin treatment based on the algorithms.
Study NCT01418703 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Open Loop
Description: This admission was to assess the subjects' level of glucose control and created a base to compare the performance of the closed-loop system. Subjects monitored their own blood glucose values and administer their basal/bolus as they would at home. Subjects use their own pump. Otherwise, the admission remained the same as in the closed-loop admission (i.e. meals, exercise, etc...).
Study NCT00615589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine/Busulfan x 4 days
Description: * Fludarabine: 40 mg/m2/day in NS, administered IV over 30 minutes on days -5, -4, -3, and -2 pre-transplant.~* Busulfan: 3.2 mg/kg IV daily in NS over 4 hours on days -5, -4, -3, and -2.~The Fludarabine shall be administered prior to the Busulfan each day.
Study NCT00615589 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stem cell transplant
Description: Allogeneic, peripheral blood stem cell transplant
Study NCT01220973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin calcium
Study NCT01220973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Study NCT01220973 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study NCT02087618 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kodro+
Description: Kodro+ participants will utilize Kodro Solution on a tablet for 30 minutes a day for 36 weeks
Study NCT02087618 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Kodro+D
Description: Kodro+D participants will utilize the Kodro Solution program 12-weeks post-baseline for 30 minutes per day for 24-weeks
Study NCT01321918 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Case Controls
Description: A blood sample of 10 ml (2 x 5 ml) on two EDTA tubes will be realised on a route of vascular development place in the context of medical practice.Clinical data will be indicated in the CRF and the computerized database. In the event an eligible patient has not been included during his support by an emergency ambulance service but, after successful resuscitation, he has been hospitalised in a cardiology department, its inclusion may be realised during the hospitalization by a physician investigator of the study. A blood sample of 10 ml of 2 EDTA tubes will be realised on a route of vascular development in the context of routine care.
Study NCT01321918 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control subjects
Description: A blood sample of 10 ml (2 x 5 ml) on two EDTA tubes will be realised and clinical data will be indicated in the CRF and the computerized database.
Study NCT03378609 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Vocal Fatigue Index (VFI)
Description: collection of 190 consecutive data sets, participants give separate consent for participating a retest or an interview, retest will be realised with the 10 following volunteers
Study NCT03952468 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: Administration of rapidly fluctuating magnetic field, delivered over the dorsolateral prefrontal cortex.
Study NCT03952468 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: Administration of rapidly fluctuating magnetic field, delivered over the dorsolateral prefrontal cortex.
Study NCT03952468 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Brief Cognitive Behavioral Therapy
Description: BCBT is a well-established and efficacious treatment that is an extension of Cognitive Behavioral Therapy, a treatment that is widely implemented across VA health care systems.
Study NCT03952468 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brief Cognitive Behavioral Therapy
Description: BCBT is a well-established and efficacious treatment that is an extension of Cognitive Behavioral Therapy, a treatment that is widely implemented across VA health care systems.
Study NCT03570918 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MGD014
Description: HIV-1 x CD3 bispecific DART molecule
Study NCT00086801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: given IV
Study NCT00086801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: given IV
Study NCT00086801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinblastine
Description: given IV
Study NCT00086801 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18 positron-emission tomography (PET) scan
Study NCT00086801 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT scan
Study NCT04086147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose tenecteplase
Description: Intravenous (IV) tenecteplase 0.25 mg/kg (single bolus; maximum dose 25 mg)
Study NCT04086147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose tenecteplase
Description: Intravenous (IV) tenecteplase 0.32 mg/kg (single bolus; maximum dose 32 mg)
Study NCT03275376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10mg
Description: Atorvastatin or placebo will be administered according to randomized allocations.